Skip to main content
. 2019 Nov;7(22):646. doi: 10.21037/atm.2019.10.54

Figure 2.

Figure 2

Loss of 4q contributes to CD8+ T cell exclusion and identifies a subset of early stage patients with high risk of death and recurrence. (A) CXCL9 mRNA expression in patients with or without 4q deletion; (B) CXCL10 mRNA expression in patients with or without 4q deletion; (C) CXCL11 mRNA expression in patients with or without 4q deletion; (D) CD8+ T cell infiltration in patients with or without 4q deletion; (E) NK cell infiltration in patients with or without 4q deletion; (F) Kaplan-Meier analysis of 4q deletion for OS in stage I & II patients; (G) Kaplan-Meier analysis of 4q deletion for RFS in stage I & II patients; (H) Kaplan-Meier analysis of 4q deletion for OS in stage III & IV patients; (I) Kaplan-Meier analysis of 4q deletion for RFS in stage III & IV patients. *, P<0.05. Del, deletion; RFS, recurrence-free survival.